Original Source(s)
Related Content
ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?
Cost and turnaround times are a potential challenge to standardization of testing and optimization of patient pathways
September 14, 2026
-
2 min
FDA approves serial liquid biopsy testing
In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.
September 8, 2026
-
2 min